These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 25926042)

  • 1. Towards the development of specific antidotes: Idarucizumab for reversal of dabigatran effects.
    Hobl EL; Jilma B
    Thromb Haemost; 2015 Jun; 113(6):1162-3. PubMed ID: 25926042
    [No Abstract]   [Full Text] [Related]  

  • 2. Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran.
    Miyares MA; Kuyumjian Y; Eaves S; Dollard E
    J Pharm Pract; 2015 Dec; 28(6):548-54. PubMed ID: 26894245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.
    Glund S; Moschetti V; Norris S; Stangier J; Schmohl M; van Ryn J; Lang B; Ramael S; Reilly P
    Thromb Haemost; 2015 May; 113(5):943-51. PubMed ID: 25789661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Waiting for the Antidote: The Journey of Idarucizumab as a Potential Specific Reversal Agent for Dabigatran (Pradaxa).
    O'Malley PA
    Clin Nurse Spec; 2015; 29(5):262-4; quiz E8. PubMed ID: 26258832
    [No Abstract]   [Full Text] [Related]  

  • 5. Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence.
    Giustozzi M; Verso M; Agnelli G; Becattini C
    J Thromb Thrombolysis; 2017 Nov; 44(4):527-535. PubMed ID: 28913672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Emerg Med; 2016 Nov; 34(11S):26-32. PubMed ID: 27707528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Administration of idarucizumab in spontaneous intracerebral hemorrhage under dabigatran-therapy].
    Bereczki D; Szilágyi G; Kakuk I; Szakács Z; May Z
    Ideggyogy Sz; 2017 Sep; 70(9-10):349-353. PubMed ID: 29870627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of dabigatran by idarucizumab: when and how?
    Vanassche T; Greinacher A; Verhamme P
    Expert Rev Hematol; 2016 Jun; 9(6):519-28. PubMed ID: 27166653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idarucizumab (Praxbind): The First Reversal Agent for a Direct Oral Anticoagulant.
    Finks SW; Rogers KC
    Am J Med; 2017 May; 130(5):e195-e197. PubMed ID: 28011314
    [No Abstract]   [Full Text] [Related]  

  • 10. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous Thrombolysis With Recombinant Tissue-Type Plasminogen Activator in a Stroke Patient Receiving Dabigatran Anticoagulant After Antagonization With Idarucizumab.
    Berrouschot J; Stoll A; Hogh T; Eschenfelder CC
    Stroke; 2016 Jul; 47(7):1936-8. PubMed ID: 27301937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose requirements for idarucizumab reversal of dabigatran in a lethal porcine trauma model with continuous bleeding.
    Honickel M; Spronk HM; Rossaint R; Stoppe C; van Ryn J; Ten Cate H; Grottke O
    Thromb Haemost; 2017 Jun; 117(7):1370-1378. PubMed ID: 28424818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment with inhibitors of new oral direct anticoagulants in patients with severe bleedings or urgent surgical procedures. The new dabigatran antidote: the place of idarucizumab in clinical practice].
    Boda Z
    Orv Hetil; 2016 Mar; 157(12):443-50. PubMed ID: 26971644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ongoing redistribution of dabigatran necessitates repetitive application of idarucizumab.
    Hegemann I; Ganter C; Widmer CC; Becker M; Müller D; Spahn DR
    Br J Anaesth; 2018 Aug; 121(2):505-508. PubMed ID: 30032897
    [No Abstract]   [Full Text] [Related]  

  • 15. Idarucizumab for dabigatran overdose in a child.
    Shapiro S; Bhatnagar N; Khan A; Beavis J; Keeling D
    Br J Haematol; 2018 Feb; 180(3):457-459. PubMed ID: 27734469
    [No Abstract]   [Full Text] [Related]  

  • 16. Volume replacement strategies do not impair the binding of dabigatran to idarucizumab: Porcine model of hemodilution.
    Grottke O; van Ryn J; Zentai C; Gan G; Honickel M; Rossaint R; Ten Cate H; Spronk HMH
    PLoS One; 2019; 14(1):e0209350. PubMed ID: 30615630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concerns about idarucizumab for dabigatran reversal.
    Stöllberger C; Pommer P; Schneider B; Finsterer J
    Blood Coagul Fibrinolysis; 2016 Jun; 27(4):473-4. PubMed ID: 27124105
    [No Abstract]   [Full Text] [Related]  

  • 18. Idarucizumab for the Reversal of Dabigatran.
    Gottlieb M; Khishfe B
    Ann Emerg Med; 2017 May; 69(5):554-558. PubMed ID: 28110992
    [No Abstract]   [Full Text] [Related]  

  • 19. Idarucizumab administration for reversing dabigatran effect in an acute kidney injured patient with bleeding.
    Quintard H; Viard D; Drici MD; Ruetsch C; Samama CM; Ichai C
    Thromb Haemost; 2017 Jan; 117(1):196-197. PubMed ID: 27734073
    [No Abstract]   [Full Text] [Related]  

  • 20. Evidence supporting idarucizumab for the reversal of dabigatran.
    Pollack CV
    Am J Emerg Med; 2016 Nov; 34(11S):33-38. PubMed ID: 27697436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.